舒血宁注射液联合蚓激酶治疗脑梗死的临床研究  

Clinical study on Shuxuening Injection combined with lumbrokinase in treatment of cerebral infarction

作　　者：牟梓樟 孔繁呈 侯立刚 

机构地区：[1]北京市房山区良乡医院(首都医科大学良乡教学医院)神经内科,北京102488

出　　处：《现代药物与临床》2018年第2期238-241,共4页Drugs & Clinic

摘　　要：目的探讨舒血宁注射液联合蚓激酶治疗脑梗死患者的临床疗效。方法收集2015年3月—2017年4月来北京市房山区良乡医院(首都医科大学良乡教学医院)就诊的脑梗死患者86例为研究对象,随机分为对照组和治疗组,每组各43例。对照组口服蚓激酶肠溶胶囊,60万单位/次,3次/d,饭前30 min口服。治疗组在对照组治疗基础上静脉滴注舒血宁注射液,20 m L/次,1次/d。两组均连续治疗14 d。观察两组的临床疗效,比较两组治疗前后神经功能缺损(NIHSS)评分、日常生活活动能力(ADL)评分、血清铁蛋白(SF)、C反应蛋白(CRP)水平的变化情况。结果治疗后,对照组和治疗组患者的总有效率分别为76.7%、93.0%,两组比较差异有统计学意义(P<0.05)。治疗后,两组NIHSS评分、SF、CRP均显著降低,ADL评分均显著升高,同组治疗前后比较差异有统计学意义(P<0.05);治疗后,治疗组NIHSS评分、SF、CRP低于对照组,ADL评分高于对照组,两组比较差异有统计学意义(P<0.05)。结论舒血宁注射液联合蚓激酶治疗脑梗死具有较好的临床疗效,能改善患者的神经功能缺损状况,明显提高患者的日常生活活动能力,具有一定的临床推广应用价值。Objective To explore the clinical curative effect of Shuxuening Injection combined with lumbrokinase in treatment of cerebral infarction. Methods Patients（86 cases） with cerebral infarction in Liangxiang Hospital of Fangshan District in Beijing（Liangxiang Teaching Hospital of Capital Medical University） from March 2015 to April 2017 were randomly divided into control（43 cases） and treatment（43 cases） groups. Patients in the control group were po administered with Lumbrokinase Enteric-coated Capsules, 6×105 U/time, three times daily. Patients in the treatment group were iv administered Shuxuening Injection on the basis of the control group, 20 m L/time, once daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy was evaluated, and the changes of NIHSS score, ADL score, and the levels of SF and CRP in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 76.7% and 93.0%, respectively, and there was difference between two groups（P〈0.05）. After treatment, NIHSS score, SF, and CRP levels in two groups were decreased, but ADL score was increased, and the difference was statistically significant in the same group（P〈0.05）. After treatment, NIHSS score, SF, and CRP levels in the treatment group were higher than those in the control group, but ADL score was lower than that in the control group, and there was difference between two groups（P〈0.05）. Conclusion Shuxuening Injection combined with lumbrokinase has clinical curative effect in treatment of cerebral infarction, and can improve the neurological deficit, and can improve daily activities, which has a certain clinical application value.

关 键 词：舒血宁注射液 蚓激酶肠溶胶囊 脑梗死 神经功能缺损评分 日常生活活动能力评分 血清铁蛋白 C反应蛋白 

分 类 号：R971[医药卫生—药品]